Bydureon: Made in the U.S.A for Europeans

Amylin Pharmaceuticals received its first regulatory approval in Europe while approval of the diabetes drug has been delayed at least a year in the US. The approval by the European Commission in June means the 300 employees Amylin has at its manufacturing facility in Ohio will switch gears from making the drugs for clinical trials to making the drugs for market. The facility is the only manufacturing facility Amylin owns, designed specifically for the production of Bydureon.